A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.

NCT01899755 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: GSK2800528, solution for injection
DRUG: Placebo (0.9% w/v Sodium Chloride), solution for injection
DRUG: Adalimumab, solution for injection

Sponsor

GlaxoSmithKline